Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients. Methods: One hundred and fifty one patients were randomised to barnidipine, 20mg/day, or lercanidipine, 20mg/day, both in addition to losartan, 100mg/day, for 6months. We assessed BP every month, in addition, patients underwent ambulatory blood pressure monitoring (ABPM). We also assessed: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), some markers such as high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble vascular adhesion protein-1 (sVCAM-1), soluble intercellular adhesion protein-1 (sICAM-1), isoprostanes and paraoxonase-1 (PON-1). Results: Both barnidipine and lercanidipine resulted in a significant reduction in blood pressure, even if the reduction obtained with barnidipine + losartan was greater than that obtained with lercanidipine + losartan. Data recorded with ABPM also showed a similar trend. Barnidipine + losartan reduced the levels of Hs-CRP, TNF-α, sVCAM-1, sICAM-1, and isoprostanes both compared to baseline and to lercanidipine + losartan. Conclusions: Barnidipine + losartan gave an improvement of some parameters indicative of endothelial damage and oxidative stress in diabetic and hypertensive patients.

Original languageEnglish
Article number66
JournalBMC Cardiovascular Disorders
Volume16
Issue number1
DOIs
Publication statusPublished - Apr 12 2016

Fingerprint

Losartan
Type 2 Diabetes Mellitus
Oxidative Stress
Hypertension
Isoprostanes
Ambulatory Blood Pressure Monitoring
C-Reactive Protein
Tumor Necrosis Factor-alpha
Aryldialkylphosphatase
Matrix Metalloproteinase 2
Glycosylated Hemoglobin A
mepirodipine
lercanidipine
Blood Vessels
Fasting
Proteins
Blood Pressure
Glucose

Keywords

  • Barnidipine
  • Losartan
  • Oxidative stress

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{11ca3f8173f9410bbef385c2203dfc40,
title = "Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus",
abstract = "Background: Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients. Methods: One hundred and fifty one patients were randomised to barnidipine, 20mg/day, or lercanidipine, 20mg/day, both in addition to losartan, 100mg/day, for 6months. We assessed BP every month, in addition, patients underwent ambulatory blood pressure monitoring (ABPM). We also assessed: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), some markers such as high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble vascular adhesion protein-1 (sVCAM-1), soluble intercellular adhesion protein-1 (sICAM-1), isoprostanes and paraoxonase-1 (PON-1). Results: Both barnidipine and lercanidipine resulted in a significant reduction in blood pressure, even if the reduction obtained with barnidipine + losartan was greater than that obtained with lercanidipine + losartan. Data recorded with ABPM also showed a similar trend. Barnidipine + losartan reduced the levels of Hs-CRP, TNF-α, sVCAM-1, sICAM-1, and isoprostanes both compared to baseline and to lercanidipine + losartan. Conclusions: Barnidipine + losartan gave an improvement of some parameters indicative of endothelial damage and oxidative stress in diabetic and hypertensive patients.",
keywords = "Barnidipine, Losartan, Oxidative stress",
author = "Giuseppe Derosa and Amedeo Mugellini and Pesce, {Rosa Maria} and Angela D'Angelo and Pamela Maffioli",
year = "2016",
month = "4",
day = "12",
doi = "10.1186/s12872-016-0237-z",
language = "English",
volume = "16",
journal = "BMC Cardiovascular Disorders",
issn = "1471-2261",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus

AU - Derosa, Giuseppe

AU - Mugellini, Amedeo

AU - Pesce, Rosa Maria

AU - D'Angelo, Angela

AU - Maffioli, Pamela

PY - 2016/4/12

Y1 - 2016/4/12

N2 - Background: Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients. Methods: One hundred and fifty one patients were randomised to barnidipine, 20mg/day, or lercanidipine, 20mg/day, both in addition to losartan, 100mg/day, for 6months. We assessed BP every month, in addition, patients underwent ambulatory blood pressure monitoring (ABPM). We also assessed: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), some markers such as high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble vascular adhesion protein-1 (sVCAM-1), soluble intercellular adhesion protein-1 (sICAM-1), isoprostanes and paraoxonase-1 (PON-1). Results: Both barnidipine and lercanidipine resulted in a significant reduction in blood pressure, even if the reduction obtained with barnidipine + losartan was greater than that obtained with lercanidipine + losartan. Data recorded with ABPM also showed a similar trend. Barnidipine + losartan reduced the levels of Hs-CRP, TNF-α, sVCAM-1, sICAM-1, and isoprostanes both compared to baseline and to lercanidipine + losartan. Conclusions: Barnidipine + losartan gave an improvement of some parameters indicative of endothelial damage and oxidative stress in diabetic and hypertensive patients.

AB - Background: Essential hypertension has been extensively reported to cause endothelial dysfunction. The aim of this study was to evaluate the effects of barnidipine or lercanidipine, in addition to losartan, on some parameters indicative of endothelial damage and oxidative stress in hypertensive, type 2 diabetic patients. Methods: One hundred and fifty one patients were randomised to barnidipine, 20mg/day, or lercanidipine, 20mg/day, both in addition to losartan, 100mg/day, for 6months. We assessed BP every month, in addition, patients underwent ambulatory blood pressure monitoring (ABPM). We also assessed: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), some markers such as high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), metalloproteinase-2 (MMP-2) and -9 (MMP-9), soluble vascular adhesion protein-1 (sVCAM-1), soluble intercellular adhesion protein-1 (sICAM-1), isoprostanes and paraoxonase-1 (PON-1). Results: Both barnidipine and lercanidipine resulted in a significant reduction in blood pressure, even if the reduction obtained with barnidipine + losartan was greater than that obtained with lercanidipine + losartan. Data recorded with ABPM also showed a similar trend. Barnidipine + losartan reduced the levels of Hs-CRP, TNF-α, sVCAM-1, sICAM-1, and isoprostanes both compared to baseline and to lercanidipine + losartan. Conclusions: Barnidipine + losartan gave an improvement of some parameters indicative of endothelial damage and oxidative stress in diabetic and hypertensive patients.

KW - Barnidipine

KW - Losartan

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84962815890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962815890&partnerID=8YFLogxK

U2 - 10.1186/s12872-016-0237-z

DO - 10.1186/s12872-016-0237-z

M3 - Article

AN - SCOPUS:84962815890

VL - 16

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

SN - 1471-2261

IS - 1

M1 - 66

ER -